AstraZeneca Reports Mixed Lung Cancer Trial Results
AstraZeneca is stopping a clinical trial of the experimental drug volrustomig as it didn’t look set to help fight lung cancer better than existing therapies. The company had two separate late-stage trial successes that strengthen key cancer franchises, including one where patients with non-small cell lung cancer received Tagrisso in combination with Orpathys. Bloomberg Intelligence's Sam Fazeli…
We haven't written up this one. Bloomberg has the full story — the link below goes straight to it.
